Upper tract urothelial carcinoma: Impact of time to surgery

被引:37
作者
Sundi, Debasish [1 ,2 ]
Svatek, Robert S. [1 ]
Margulis, Vitaly [1 ,3 ]
Wood, Christopher G. [1 ]
Matin, Surena F. [1 ]
Dinney, Colin P. [1 ]
Kamat, Ashish M. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol Oncol, Houston, TX 77030 USA
[2] Johns Hopkins Univ Hosp, Brady Inst Urol, Baltimore, MD 21287 USA
[3] Univ Texas SW, Dept Urol, Dallas, TX 75390 USA
关键词
Upper tract urothelial carcinoma; Delayed surgery; Nephroureterectomy; Neoadjuvant chemotherapy; TRANSITIONAL-CELL CARCINOMA; UPPER URINARY-TRACT; NEOADJUVANT CHEMOTHERAPY; MUSCLE INVASION; BLADDER-CANCER; CYSTECTOMY; NEPHROURETERECTOMY; MANAGEMENT; DIAGNOSIS; SURVIVAL;
D O I
10.1016/j.urolonc.2010.04.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Patients diagnosed with upper tract urothelial carcinoma (UTUC) sometimes experience a delay from diagnosis to extirpative surgery (nephroureterectomy or ureterectomy) as a result of attempted endoscopic management and/or neoadjuvant chemotherapy. The purpose of this analysis is to examine the impact of such delay on survival outcomes. Methods: An IRB-approved retrospective review identified consecutive patients undergoing extirpative surgery for UTUC treated at a single institution between 1990 and 2007. 240 patients with non-metastatic disease represented both primarily-presenting and referred patients. Patients in the "early" surgery group underwent extirpative surgery <3 months after diagnosis and patients in the "delayed" surgery group underwent surgery months after diagnosis. Timing to surgery was at the discretion of individual patient-surgeon decision-making. Analyses and measurements were univariate and multivariate models correlating death from disease with clinico-pathologic parameters, recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in the "early" and "delayed" surgery groups. Results: 186 patients underwent early surgery and 54 patients underwent delayed surgery. Median follow-up for all patients was 29 months. The 5-year CSS were 72% and 71% for the early versus late groups, respectively (P = 0.39) and corresponding 5-year OS rates were 60% and 69%, respectively (P = 0.69). Delay in surgery was not associated with a worse outcome, even following adjustment for potential confounders. The most common factor contributing to delayed surgery in our cohort was administration of neoadjuvant chemotherapy (50%), which did not impact survival. Limitations included a median follow-up of 19 months in the neoadjuvant group; and the requirement to analytically group pathologic high-stage and low-stage disease, which reflects challenges inherent to current clinical staging. Conclusions: Our results show no difference in survival between patients undergoing early versus delayed extirpative surgery for UTUC, suggesting the feasibility of delayed surgery in appropriately selected patients. Only prospective validation of delayed surgery can guarantee its safety. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:266 / 272
页数:7
相关论文
共 22 条
[1]   The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma - A Phase II study of the Hellenic Cooperative Oncology Group [J].
Bamias, A ;
Moulopoulos, LA ;
Koutras, A ;
Aravantinos, G ;
Fountzilas, G ;
Pectasides, D ;
Kastritis, E ;
Gika, D ;
Skarlos, D ;
Linardou, H ;
Kalofonos, HP ;
Dimopoulos, MA .
CANCER, 2006, 106 (02) :297-303
[2]   Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: A study by the Hellenic Cooperative Oncology Group [J].
Bamias, A ;
Deliveliotis, C ;
Fountzilas, G ;
Gika, D ;
Anagnostopoulos, A ;
Zorzou, MP ;
Kastritis, E ;
Constantinides, C ;
Kosmidis, P ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2150-2154
[3]   Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma [J].
Boorjian, S ;
Ng, C ;
Munver, R ;
Palese, MA ;
Vaughan, ED ;
Sosa, RE ;
Del Pizzo, JJ ;
Scherr, DS .
UROLOGY, 2005, 66 (02) :283-287
[4]   Ability of clinical grade to predict final Pathologic stage in upper urinary tract transitional cell carcinoma: Implications for therapy [J].
Brown, Gordon A. ;
Matin, Surena F. ;
Busby, J. Erik ;
Dinney, Colin P. N. ;
Grossman, H. Barton ;
Pettaway, Curtis A. ;
Munsell, Mark F. ;
Kamat, Ashish M. .
UROLOGY, 2007, 70 (02) :252-256
[5]   Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm? [J].
Brown, Gordon A. ;
Busby, J. Erik ;
Wood, Christopher G. ;
Pisters, Louis L. ;
Dinney, Colin P. N. ;
Swanson, David A. ;
Grossman, H. Barton ;
Pettaway, Curtis A. ;
Munsell, Mark F. ;
Kamat, Ashish M. ;
Matin, Surena F. .
BJU INTERNATIONAL, 2006, 98 (06) :1176-1180
[6]   Endoscopic management of upper urinary tract transitional cell carcinoma - Long-term experience [J].
Daneshmand, S ;
Quek, ML ;
Huffman, JL .
CANCER, 2003, 98 (01) :55-60
[7]   Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].
Grossman, HB ;
Natale, RB ;
Tangen, CM ;
Speights, VO ;
Vogelzang, NJ ;
Trump, DL ;
White, RWD ;
Sarosdy, MF ;
Wood, DP ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866
[8]   Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients [J].
Hall, MC ;
Womack, S ;
Sagalowsky, AI ;
Carmody, T ;
Erickstad, MD ;
Roehrborn, CG .
UROLOGY, 1998, 52 (04) :594-601
[9]   NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED UROTHELIAL CANCER OF THE UPPER URINARY-TRACT [J].
IGAWA, M ;
URAKAMI, S ;
SHIINA, H ;
KISHI, H ;
HIMENO, Y ;
ISHIBE, T ;
USUI, T .
UROLOGIA INTERNATIONALIS, 1995, 55 (02) :74-77
[10]   Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma [J].
Keeley, FX ;
Bibbo, M ;
Bagley, DH .
JOURNAL OF UROLOGY, 1997, 157 (05) :1560-1565